7,399 Shares in United Therapeutics Corporation $UTHR Purchased by Great Lakes Advisors LLC

Great Lakes Advisors LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 7,399 shares of the biotechnology company’s stock, valued at approximately $4,009,000.

Other large investors also recently added to or reduced their stakes in the company. Arjuna Capital boosted its stake in United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC raised its position in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC lifted its holdings in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares in the last quarter. Meeder Advisory Services Inc. boosted its position in shares of United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 26 shares during the last quarter. Finally, Independent Advisor Alliance boosted its position in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after acquiring an additional 27 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $170,968,483.28. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $517.05, for a total value of $4,291,515.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,356,182.60. This trade represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 434,275 shares of company stock valued at $234,984,268. 8.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $515.00 price target on United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada reduced their price objective on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $646.00.

United Therapeutics Stock Down 1.5%

UTHR stock opened at $521.00 on Friday. United Therapeutics Corporation has a twelve month low of $302.19 and a twelve month high of $609.35. The stock has a market capitalization of $22.35 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 1.79 and a beta of 0.59. The firm’s fifty day simple moving average is $533.74 and its two-hundred day simple moving average is $537.53.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the prior year, the firm posted $6.41 earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, equities research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.